Elite Pharmaceuticals, Inc.
ELTP · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $84 | $57 | $34,155 | $32 |
| % Growth | 48.4% | -99.8% | 105,767.6% | – |
| Cost of Goods Sold | $44 | $30 | $17,561 | $17 |
| Gross Profit | $40 | $26 | $16,594 | $15 |
| % Margin | 47.7% | 46.5% | 48.6% | 45.9% |
| R&D Expenses | $8 | $7 | $6,200 | $4 |
| G&A Expenses | $9 | $7 | $5,122 | $4 |
| SG&A Expenses | $9 | $7 | $5,122 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $3 | $1 | $1,596 | $1 |
| Operating Expenses | $20 | $16 | $12,918 | $10 |
| Operating Income | $20 | $11 | $2,025 | $5 |
| % Margin | 23.3% | 19.1% | 5.9% | 15.7% |
| Other Income/Exp. Net | -$20 | -$10 | $0 | $2 |
| Pre-Tax Income | -$0 | $0 | $3,986 | $7 |
| Tax Expense | $4 | -$20 | -$424 | -$2 |
| Net Income | -$4 | $20 | $4,410 | $9 |
| % Margin | -5.1% | 35.5% | 12.9% | 27.6% |
| EPS | -0.004 | 0.02 | 4.35 | 0.009 |
| % Growth | -120.2% | -99.5% | 49,331.8% | – |
| EPS Diluted | -0.004 | 0.02 | 4.35 | 0.007 |
| Weighted Avg Shares Out | 1,068 | 1,015 | 1,013 | 1,011 |
| Weighted Avg Shares Out Dil | 1,068 | 1,023 | 1,013 | 1,011 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $0 |
| Depreciation & Amortization | $2 | $1 | $1 | $1 |
| EBITDA | $3 | $3 | $6 | $6 |
| % Margin | 3.4% | 4.5% | 0% | 20.1% |